Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...

Despite advancements in early detection and innovative treatments, Black women in the United States face higher mortality ...

The FDA has approved Rybrevant in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ...

The greatest disparity in BC-specific survival was observed in women with HR+ HER2− tumors, with Black women having a 50% ...

HER3 (also known as ERBB3) is a crucial member of the Epidermal Growth Factor Receptor (EGFR) family. It plays a significant role in cellular proliferation, survival, and differentiation via the ...

Results have been positive, with SHR-1701 demonstrating improvements in overall survival, but taking market share will be a ...

The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages ...

Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or ...

Although endocrine therapy remains the mainstay of treatment for hormone receptor–positive/human epidermal growth factor receptor 2–negative mBC, significant progress has been and continues to be made ...

Stimulation of epidermal keratinocytes by insulin-like growth factor I (IGF-I ... We hypothesized that inhibition of IGF-I receptor expression in the psoriasis lesion would reverse psoriatic ...

[10] Epidermal growth factor receptor is a member of the erbB/human epidermal growth factor receptor family of tyrosine kinases, which includes erbB2/HER2, erbB3/ HER3 and erbB4/HER4. Epidermal ...